Moffitt Cancer Center Executive Leadership
Dana Rollison, PhD
Vice President and Chief Data Officer; Associate Center Director of Data Science
Dr. Dana Rollison is the Vice President, Chief Data Officer (VP, CDO) and Associate Center Director (ACD) of Data Science at Moffitt Cancer Center in Tampa, FL. Dr. Rollison joined the research faculty at Moffitt Cancer Center in 2004, after earning her undergraduate degree in biology with honors from the University of Miami and completing her master's, doctoral and postdoctoral training in cancer epidemiology at Johns Hopkins University. Currently a Senior Member, her research focuses on the application of data science techniques to unravel cancer etiology, enhance cancer surveillance and advance care delivery. As VP, CDO and ACD of Data Science, Dr. Rollison drives innovation in three key areas:
- Administrative leadership of Health Data Services, including four departments dedicated to providing access to high-quality patient data and associated insights: Cancer Registry, Data Quality & Business Intelligence, Health Informatics, and Advanced Analytics.
- Strategic visioning for Moffitt’s Cancer Analytics Platform (MCAP), the center’s cloud-based enterprise-wide data warehouse and analytics hub, and executive leadership of Moffitt’s Enterprise Wide Analytics Strategy (EWAS) and associated data governance committees, bringing together clinical and research faculty and operational leaders in support of translational research, accountable care analytics, and the practice of personalized medicine.
- Scientific leadership of the Division of Quantitative Science within the Moffitt Research Institute, including the academic departments of Biostatistics and Bioinformatics, Integrated Mathematical Oncology, Machine Learning and multiple data-related shared resources.
Leveraging her dual role as CDO and ACD, Dr. Rollison seeks to orchestrate and optimize Moffitt’s extensive data assets across clinical, research and operational areas of the organization, thus accelerating scientific discovery and ultimately improving patient outcomes across the cancer continuum.